Phase 2A, Single Center, Open-label, Single-arm, 24-week Study to Evaluate the Safety, Tolerability and Efficacy of Saroglitazar Magnesium 4 mg in Liver Transplant Recipients With Nonalcoholic Fatty Liver Disease (EVIDENCES VIII)
Latest Information Update: 28 Oct 2024
At a glance
- Drugs Saroglitazar (Primary)
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms EVIDENCES VIII
- Sponsors Zydus Discovery DMCC
- 14 Nov 2023 Results presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases
- 06 Oct 2023 Status changed from recruiting to completed.
- 28 Feb 2023 Results assessing the safety and efficacy of saroglitazar on treatment of post-LT NAFLD and metabolic burden, published in the Liver Transplantation.